The U.S. Supreme Court says it will not hear an appeal from Johnson & Johnson’s subsidiary, Janssen, which had been penalized $124 million for deceptive marketing of its anti-psychotic drug, Risperdal. The federal district court has entered a ruling that Janssen Pharmaceuticals Inc. should pay penalties for violating South Carolina law. In 2011, it was found that Janssen had been downplaying the effects of its drug Risperdal by claiming that it was safer than other similar competing medications.
The total penalty of $124 million for deceptive marketing was the largest drug marketing award in state history and largest penalty levied for violations of the South Carolina Unfair Trade Practices Act.
It was claimed that Janssen knew that Risperdal was related to health problems that they hid from doctors. Instead, Janssen publicized studies that it claimed were evidence that the drug lowered incidences of diabetes and weight gain when compared to other similar medicines. Those claims were false.